Organized by Xi’an Jiaotong University , Communications AI & Computing, Nature, Nature Energy, Nature Sustainability, Communications Materials and Nature Machine Intelligence.
Artificial intelligence is rapidly reshaping how materials are discovered, designed and deployed to address the world’s most pressing sustainability challenges. AI for Sustainable Materials brings together leading researchers, innovators and stakeholders at the intersection of materials science, data science and environmental sustainability for a focused, forward-looking discussion curated by the Nature Portfolio editorial team.
Across three days, the conference will explore how advances in artificial intelligence can accelerate the development of environmentally responsible materials, while also considering how materials innovation can, in turn, enable more efficient and sustainable AI.
Register Now Submit Abstract Deadline: Sep.27, 2026 Contact Us
Event details
Speakers
Hongyun Zhao
Sun Yat-sen University Cancer Center, China
Ira Mellman
Parker Institute for Cancer Immunotherapy and Medici Therapeutics, USA
Ira Mellman (FAACR, FAIO) is President of Research at the Parker Institute of Cancer Immunotherapy (PICI) and CSO of Medici Therapeutics, both in San Francisco, California. An expert in cancer vaccines, Ira is a member of the US National Academy of Sciences and former VP of Cancer Immunology at Genentech, Sterling Professor of Cell Biology & Immunobiology at Yale Medical School, and a postdoctoral fellow with Ralph Steinman at The Rockefeller University. Ira is best known for fundamental advances in cell biology and immunology (particularly the discovery of endosomes) and for applying these insights to elucidate the mechanisms of antigen processing by dendritic cells and the basis of PD-1/PD-L1 inhibition; Ira was also responsible for devising the Cancer Immunity Cycle framework. At Genentech, his group discovered or developed four FDA-approved cancer agents, including the anti-PD-L1 antibody atezolizumab (Tecentriq®); he is also credited with initiating the first personalized mRNA cancer vaccine in collaboration with BioNTech and Memorial Sloan Kettering Cancer Center. Ira is the recipient of the 2025 Richard Smalley award of the Society for the Immunotherapy of Cancer and the Lloyd J. Old Award for Cancer Immunotherapy from the American Association for Cancer Research.